Department of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
Institute for Diabetes, Obesity, and Metabolism, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
EMBO Mol Med. 2021 May 7;13(5):e13524. doi: 10.15252/emmm.202013524. Epub 2021 Apr 6.
Pancreatic beta cells undergo compensatory proliferation in the early phase of type 2 diabetes. While pathways such as FoxM1 are involved in regulating compensatory beta cell proliferation, given the lack of therapeutics effectively targeting beta cell proliferation, other targetable pathways need to be identified. Herein, we show that Pbk, a serine/threonine protein kinase, is essential for high fat diet (HFD)-induced beta cell proliferation in vivo using a Pbk kinase deficiency knock-in mouse model. Mechanistically, JunD recruits menin and HDAC3 complex to the Pbk promoter to reduce histone H3 acetylation, leading to epigenetic repression of Pbk expression. Moreover, menin inhibitor (MI) disrupts the menin-JunD interaction and augments Pbk transcription. Importantly, MI administration increases beta cell proliferation, ameliorating hyperglycemia, and impaired glucose tolerance (IGT) in HFD-induced diabetic mice. Notably, Pbk is required for the MI-induced beta cell proliferation and improvement of IGT. Together, these results demonstrate the repressive role of the menin/JunD/Pbk axis in regulating HFD-induced compensatory beta cell proliferation and pharmacologically regulating this axis may serve as a novel strategy for type 2 diabetes therapy.
胰岛β细胞在 2 型糖尿病的早期会发生代偿性增殖。虽然 FoxM1 等途径参与调节代偿性β细胞增殖,但由于缺乏有效针对β细胞增殖的治疗方法,需要确定其他可靶向的途径。本文中,我们利用 Pbk 激酶缺陷敲入小鼠模型表明,丝氨酸/苏氨酸蛋白激酶 Pbk 在高脂肪饮食(HFD)诱导的体内β细胞增殖中是必需的。在机制上,JunD 将 menin 和 HDAC3 复合物募集到 Pbk 启动子,以减少组蛋白 H3 的乙酰化,从而导致 Pbk 表达的表观遗传抑制。此外,menin 抑制剂(MI)破坏了 menin-JunD 相互作用,增强了 Pbk 转录。重要的是,MI 给药增加了β细胞增殖,改善了 HFD 诱导的糖尿病小鼠的高血糖和糖耐量受损(IGT)。值得注意的是,Pbk 是 MI 诱导的β细胞增殖和 IGT 改善所必需的。总之,这些结果表明 menin/JunD/Pbk 轴在调节 HFD 诱导的代偿性β细胞增殖中的抑制作用,并且对该轴的药理学调节可能成为 2 型糖尿病治疗的新策略。